Crossmark

Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR +) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling

Crossref DOI link: https://doi.org/10.1007/s12609-022-00461-3

Published Online: 2022-09-16

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Brett, Jamie O.

Herman, Paige E.

Mayer, Erica L.

Bardia, Aditya

Wander, Seth A. https://orcid.org/0000-0002-4127-4708
License Information

Text and Data Mining valid from 2022-09-16

Version of Record valid from 2022-09-16
More Information

Article History

Accepted: 29 August 2022

First Online: 16 September 2022

Declarations

:

: E. L. Mayer reports consulting for Novartis, Eli Lilly, Gilead, and AstraZeneca. A. Bardia reports consulting for Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics, Taiho, Sanofi, Daiichi Pharma/AstraZeneca, Puma Biotechnology, Biothernostics Inc., Phillips, Eli Lilly, and Foundation Medicine; and contracted research (via institution) with Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics, and Daiichi Pharma/AstraZeneca. S. A. Wander reports consulting/advisory board for Foundation Medicine, Veracyte, Eli Lilly, Hologic, Pfizer, and Biovica; and institutional research support from Genentech, Eli Lilly, Nuvation, and Regor. The other authors declare no potential conflicts of interest.

: This article does not contain any studies with human or animal subjects performed by any of the authors.

Document is current

Any future updates will be listed below